These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 30033225)

  • 21. Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer: A Clinical Commentary.
    Stein CA
    Clin Genitourin Cancer; 2015 Oct; 13(5):407-9. PubMed ID: 26119230
    [No Abstract]   [Full Text] [Related]  

  • 22. Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification.
    Priemer DS; Montironi R; Wang L; Williamson SR; Lopez-Beltran A; Cheng L
    Endocr Pathol; 2016 Jun; 27(2):123-35. PubMed ID: 26885643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?
    Konac E; Kiliccioglu I; Sogutdelen E; Dikmen AU; Albayrak G; Bilen CY
    Exp Biol Med (Maywood); 2017 Dec; 242(18):1795-1801. PubMed ID: 28836852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.
    Lin D; Dong X; Wang K; Wyatt AW; Crea F; Xue H; Wang Y; Wu R; Bell RH; Haegert A; Brahmbhatt S; Hurtado-Coll A; Gout PW; Fazli L; Gleave ME; Collins CC; Wang Y
    Oncotarget; 2015 Jan; 6(3):1806-20. PubMed ID: 25544761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer.
    Ren S; Liu Y; Xu W; Sun Y; Lu J; Wang F; Wei M; Shen J; Hou J; Gao X; Xu C; Huang J; Zhao Y; Sun Y
    J Urol; 2013 Dec; 190(6):2278-87. PubMed ID: 23845456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. There is no current role for molecular phenotyping in metastatic castrate-resistant prostate cancer.
    Vogelzang NJ
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):580-5. PubMed ID: 26452189
    [No Abstract]   [Full Text] [Related]  

  • 27. Exosomal microRNAs as potential biomarkers in castration-resistant prostate cancer.
    Haflidadóttir BS; Ceder Y
    Eur Urol; 2015 Jan; 67(1):42-43. PubMed ID: 25199715
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical phenotypes of castration-resistant prostate cancer.
    Zhang T; Armstrong AJ
    Clin Adv Hematol Oncol; 2013 Nov; 11(11):707-18. PubMed ID: 24896544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S; Arai Y
    Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclin-Dependent Kinase 12, Immunity, and Prostate Cancer.
    Antonarakis ES
    N Engl J Med; 2018 Sep; 379(11):1087-1089. PubMed ID: 30207914
    [No Abstract]   [Full Text] [Related]  

  • 31. Re: Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
    Taneja SS
    J Urol; 2015 Sep; 194(3):704. PubMed ID: 26292859
    [No Abstract]   [Full Text] [Related]  

  • 32. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.
    Bryce AH; Antonarakis ES
    Int J Urol; 2016 Aug; 23(8):646-53. PubMed ID: 27255944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate cancer: Multilayered mutation analysis indicates divergent clonal evolution.
    Thoma C
    Nat Rev Urol; 2016 Apr; 13(4):179. PubMed ID: 26902334
    [No Abstract]   [Full Text] [Related]  

  • 36. [Androgen receptor variants in prostate cancer].
    Schreyer E; Barthélémy P; Cottard F; Ould Madi-Berthélémy P; Schaff-Wendling F; Kurtz JE; Céraline J
    Med Sci (Paris); 2017; 33(8-9):758-764. PubMed ID: 28945566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The time for molecular phenotyping of metastatic castrate-resistant prostate cancer is now.
    VanderWeele DJ
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):580-3. PubMed ID: 26452188
    [No Abstract]   [Full Text] [Related]  

  • 38. Molecular characterization of prostate cancer following androgen deprivation: the devil in the details.
    Barbieri CE; Rubin MA
    Eur Urol; 2014 Jul; 66(1):40-1. PubMed ID: 24011425
    [No Abstract]   [Full Text] [Related]  

  • 39. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histological Transformation to Large Cell Neuroendocrine Carcinoma from Lung Adenocarcinoma Harboring an EGFR Mutation: An Autopsy Case Report.
    Moriya R; Hokari S; Shibata S; Koizumi T; Tetsuka T; Ito K; Hashidate H; Tsukada H
    Intern Med; 2017; 56(15):2013-2017. PubMed ID: 28768973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.